Aclaris Drug Patent Portfolio
Aclaris owns 1 orange book drug protected by 6 US patents Given below is the list of Aclaris's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9675639 | Peroxide formulations and methods and applicators for using the same | 04 Jul, 2035 | Active |
| US10098910 | Peroxide formulations and methods and applicators for using the same | 21 Apr, 2035 | Active |
| US10493103 | Peroxide formulations and methods and applicators for using the same | 21 Apr, 2035 | Active |
| US10729720 | Peroxide formulations and methods and applicators for using the same | 21 Apr, 2035 | Active |
| US9980983 | Peroxide formulations and methods and applicators for using the same | 21 Apr, 2035 | Active |
| US7381427 | Seborrheic keratosis treatment | 08 Jun, 2022 | Expired |
Latest Legal Activities on Aclaris's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aclaris.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 08 Jan, 2024 | US10493103 |
|
Maintenance Fee Reminder Mailed
Critical
| 24 Jul, 2023 | US10493103 |
|
Expire Patent
Critical
| 21 Nov, 2022 | US10098910 |
| Post Issue Communication - Certificate of Correction | 18 Nov, 2022 | US9675639 |
|
Email Notification
Critical
| 19 Sep, 2022 | US9675639 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 19 Sep, 2022 | US9675639 |
|
Correspondence Address Change
Critical
| 13 Sep, 2022 | US9675639 |
|
Maintenance Fee Reminder Mailed
Critical
| 06 Jun, 2022 | US10098910 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Apr, 2022 | US10493103 |
|
Email Notification
Critical
| 14 Apr, 2022 | US10493103 |
|
Email Notification
Critical
| 13 Apr, 2022 | US7381427 |
|
Correspondence Address Change
Critical
| 13 Apr, 2022 | US10493103 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 13 Apr, 2022 | US7381427 |
|
Correspondence Address Change
Critical
| 12 Apr, 2022 | US7381427 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Dec, 2021 | US9980983 |
Aclaris's Family Patents
Aclaris drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 35.0% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Aclaris Drug List
Given below is the complete list of Aclaris's drugs and the patents protecting them.
1. Eskata
Eskata is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9675639 | Peroxide formulations and methods and applicators for using the same |
04 Jul, 2035
(10 years from now)
| Active |
| US10098910 | Peroxide formulations and methods and applicators for using the same |
21 Apr, 2035
(10 years from now)
| Active |
| US10493103 | Peroxide formulations and methods and applicators for using the same |
21 Apr, 2035
(10 years from now)
| Active |
| US10729720 | Peroxide formulations and methods and applicators for using the same |
21 Apr, 2035
(10 years from now)
| Active |
| US9980983 | Peroxide formulations and methods and applicators for using the same |
21 Apr, 2035
(10 years from now)
| Active |
| US7381427 | Seborrheic keratosis treatment |
08 Jun, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eskata's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List